New drug combo targets tough cancers in early trial
NCT ID NCT03257761
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system attack tumors. The main goals are to find the safest dose and see if the combination can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guadecitabine and durvalumab
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread.
- What could go wrong
- This is an early phase 1 trial with only 55 participants, so the main goal is safety and dosing, not proof of effectiveness. The cancers studied are very hard to treat, and the combination may not shrink tumors or extend life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAHEPATIC BILE DUCT ADENOCARCINOMA, BILIARY TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Experimental drug hopes to boost chemo against tough pancreatic cancer